These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. Oki R; Izumi Y; Fujita K; Miyamoto R; Nodera H; Sato Y; Sakaguchi S; Nokihara H; Kanai K; Tsunemi T; Hattori N; Hatanaka Y; Sonoo M; Atsuta N; Sobue G; Shimizu T; Shibuya K; Ikeda K; Kano O; Nishinaka K; Kojima Y; Oda M; Komai K; Kikuchi H; Kohara N; Urushitani M; Nakayama Y; Ito H; Nagai M; Nishiyama K; Kuzume D; Shimohama S; Shimohata T; Abe K; Ishihara T; Onodera O; Isose S; Araki N; Morita M; Noda K; Toda T; Maruyama H; Furuya H; Teramukai S; Kagimura T; Noma K; Yanagawa H; Kuwabara S; Kaji R; JAMA Neurol; 2022 Jun; 79(6):575-583. PubMed ID: 35532908 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. ; Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181 [TBL] [Abstract][Full Text] [Related]
4. [JETALS: The Japanese Early-stage Trial of high dose methylcobalamin for ALS]. Izumi Y; Oki R; Kuwabara S; Kaji R Brain Nerve; 2019 Nov; 71(11):1261-1269. PubMed ID: 31722312 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B; Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198 [TBL] [Abstract][Full Text] [Related]
6. [Clinical trials of ultra-high-dose methylcobalamin in ALS]. Izumi Y; Kaji R Brain Nerve; 2007 Oct; 59(10):1141-7. PubMed ID: 17969354 [TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effect of ultra-high dose methylcobalamin in wobbler mouse model of amyotrophic lateral sclerosis. Ikeda K; Iwasaki Y; Kaji R J Neurol Sci; 2015 Jul; 354(1-2):70-4. PubMed ID: 25982504 [TBL] [Abstract][Full Text] [Related]
8. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Cudkowicz ME; van den Berg LH; Shefner JM; Mitsumoto H; Mora JS; Ludolph A; Hardiman O; Bozik ME; Ingersoll EW; Archibald D; Meyers AL; Dong Y; Farwell WR; Kerr DA; Lancet Neurol; 2013 Nov; 12(11):1059-67. PubMed ID: 24067398 [TBL] [Abstract][Full Text] [Related]
9. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation). WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915 [TBL] [Abstract][Full Text] [Related]
10. Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis. Takahashi F; Takei K; Tsuda K; Palumbo J Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):32-39. PubMed ID: 28872914 [TBL] [Abstract][Full Text] [Related]
11. Ultra-high dose methylcobalamin and other emerging therapies for amyotrophic lateral sclerosis. Kaji R; Izumi Y; Oki R Curr Opin Neurol; 2024 Oct; 37(5):593-602. PubMed ID: 39083229 [TBL] [Abstract][Full Text] [Related]
12. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial. Urbi B; Broadley S; Bedlack R; Russo E; Sabet A BMJ Open; 2019 Nov; 9(11):e029449. PubMed ID: 31719072 [TBL] [Abstract][Full Text] [Related]
13. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. Witzel S; Maier A; Steinbach R; Grosskreutz J; Koch JC; Sarikidi A; Petri S; Günther R; Wolf J; Hermann A; Prudlo J; Cordts I; Lingor P; Löscher WN; Kohl Z; Hagenacker T; Ruckes C; Koch B; Spittel S; Günther K; Michels S; Dorst J; Meyer T; Ludolph AC; JAMA Neurol; 2022 Feb; 79(2):121-130. PubMed ID: 35006266 [TBL] [Abstract][Full Text] [Related]
14. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. Graf M; Ecker D; Horowski R; Kramer B; Riederer P; Gerlach M; Hager C; Ludolph AC; Becker G; Osterhage J; Jost WH; Schrank B; Stein C; Kostopulos P; Lubik S; Wekwerth K; Dengler R; Troeger M; Wuerz A; Hoge A; Schrader C; Schimke N; Krampfl K; Petri S; Zierz S; Eger K; Neudecker S; Traufeller K; Sievert M; Neundörfer B; Hecht M; J Neural Transm (Vienna); 2005 May; 112(5):649-60. PubMed ID: 15517433 [TBL] [Abstract][Full Text] [Related]
15. The Japanese Early-Stage Trial of High-Dose Methylcobalamin for Amyotrophic Lateral Sclerosis (JETALS): Protocol for a Randomized Controlled Trial. Oki R; Izumi Y; Nodera H; Sato Y; Nokihara H; Kanai K; Sonoo M; Urushitani M; Nishinaka K; Atsuta N; Kohara N; Shimizu T; Kikuchi H; Oda M; Ikeda K; Nagai M; Komai K; Kojima Y; Kuzume D; Isose S; Shimohama S; Abe K; Ito H; Noda K; Ishihara T; Morita M; Shimohata T; Teramukai S; Kagimura T; Noma K; Yanagawa H; Kuwabara S; Kaji R; JMIR Res Protoc; 2018 Dec; 7(12):e12046. PubMed ID: 30578206 [TBL] [Abstract][Full Text] [Related]
16. Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial. Al-Chalabi A; Shaw P; Leigh PN; van den Berg L; Hardiman O; Ludolph A; Aho VV; Sarapohja T; Kuoppamäki M J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1165-1170. PubMed ID: 31315908 [TBL] [Abstract][Full Text] [Related]
17. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. EDARAVONE (MCI-186) ALS 16 STUDY GROUP Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):11-19. PubMed ID: 28872917 [TBL] [Abstract][Full Text] [Related]
18. Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 17 STUDY GROUP Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):20-31. PubMed ID: 28872918 [TBL] [Abstract][Full Text] [Related]
19. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):55-63. PubMed ID: 28872920 [TBL] [Abstract][Full Text] [Related]
20. Effect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: a double-blind controlled study. Kaji R; Kodama M; Imamura A; Hashida T; Kohara N; Ishizu M; Inui K; Kimura J Muscle Nerve; 1998 Dec; 21(12):1775-8. PubMed ID: 9843082 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]